Business Wire

OSE Immunotherapeutics Receives €5.2 M in Public Funding for the Clinical Development of CoVepiT, Its Second Generation COVID-19 Vaccine

In Phase 2 in pancreatic cancer (TEDOPaM, sponsor GERCOR) in monotherapy and in combination with checkpoint inhibitor Opdivo ®. CoVepiT: a prophylactic vaccine against COVID-19, developed using ...
Business Wire

OSE Immunotherapeutics Receives First Notice of Allowance of a Patent for Use of Tedopi® after Failure with PD-1 or PD-L1 Immune Checkpoint Inhibitor Treatment in HLA-A2 ...

NANTES, France--(BUSINESS WIRE)--Regulatory News: OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE) today announced that the Japanese Patent Office has issued the notice of ...